Scarica l'app Stockscreener
10.82
9.23%
-1.10
Dopo l'orario di chiusura:
10.91
0.09
+0.83%
Precedente Chiudi:
$11.92
Aprire:
$11.9
Volume 24 ore:
1.16M
Relative Volume:
0.98
Capitalizzazione di mercato:
$639.21M
Reddito:
-
Utile/perdita netta:
$-153.16M
Rapporto P/E:
-2.9322
EPS:
-3.69
Flusso di cassa netto:
$-134.48M
1 W Prestazione:
-13.02%
1M Prestazione:
+26.55%
6M Prestazione:
+25.67%
1 anno Prestazione:
-7.91%
Intervallo 1D:
$10.76
$12.09
Intervallo di 1 settimana:
$10.76
$13.10
Portata 52W:
$5.68
$13.33
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Nome
Cullinan Therapeutics Inc
Settore
Industria
Telefono
617-410-4650
Indirizzo
ONE MAIN STREET, CAMBRIDGE
Confronta CGEM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
10.82 | 704.19M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-21 | Ripresa | H.C. Wainwright | Buy |
| 2025-06-11 | Ripresa | Stifel | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-05-01 | Iniziato | Stifel | Buy |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-06-15 | Iniziato | TD Cowen | Outperform |
| 2022-11-21 | Iniziato | BTIG Research | Buy |
| 2021-04-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Iniziato | Evercore ISI | Outperform |
| 2021-02-02 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Iniziato | SVB Leerink | Outperform |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates - Yahoo Finance UK
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.5%What's Next? - MarketBeat
20 Stocks That Will Double in 2026 - Insider Monkey
Weekly Research Analysts’ Ratings Updates for Cullinan Therapeutics (CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $34.00 at Wedbush - Defense World
Wedbush Maintains Cullinan Therapeutics (CGEM) Outperform Recommendation - Nasdaq
Cullinan Therapeutics shows rising price performance with jump to 93 RS rating - MSN
Holdings of Cullinan Therapeutics Inc (CGEM) are aligned with the stars - setenews.com
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $34.00 - MarketBeat
Wedbush Raises Price Target on CGEM to $34, Maintains Outperform - GuruFocus
CGEM: CLN-049 demonstrates strong efficacy and safety in AML, advancing toward pivotal trials - TradingView — Track All Markets
Cullinan Therapeutics (NASDAQ:CGEM) Trading 9.3% HigherWhat's Next? - MarketBeat
Cullinan Oncology stock soars after promising AML treatment results By Investing.com - Investing.com Canada
Cullinan’s leukemia drug shows promising results in clinical trial By Investing.com - Investing.com South Africa
Cullinan Therapeutics Presents Promising CLN-049 Data - TipRanks
Cullinan Therapeutics (CGEM) Reveals Encouraging Phase 1 Data fo - GuruFocus
Cullinan Therapeutics Reports Promising Phase 1 Data for CLN-049 in Patients with Relapsed/Refractory AML, Receives FDA Fast Track Designation - Quiver Quantitative
Cullinan Therapeutics Showcases Compelling Clinical Data in - GlobeNewswire
Cullinan Therapeutics presents promising CLN-049 data - MSN
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Investment Review: Will Cullinan Therapeutics Inc stock deliver better than expected guidance2025 Dividend Review & Breakout Confirmation Alerts - moha.gov.vn
Why Cullinan Therapeutics Inc. stock could benefit from AI revolution2025 Volatility Report & Weekly Hot Stock Watchlists - Newser
How Cullinan Therapeutics Inc. stock benefits from strong dollarJuly 2025 EndofMonth & High Conviction Buy Zone Picks - Newser
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%What's Next? - MarketBeat
There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - setenews.com
How Cullinan Therapeutics Inc. stock responds to policy changesEarnings Risk Summary & Free Weekly Watchlist of Top Performers - Newser
FDA grants fast track designation to Cullinan’s AML therapy By Investing.com - Investing.com Australia
Cullinan Oncology stock rises after FDA Fast Track designation for leukemia drug - Investing.com Canada
Cullinan Therapeutics receives FDA fast track designation for CLN-049 - marketscreener.com
CGEM Receives FDA Fast Track for CLN-049 in Leukemia Treatment - GuruFocus
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - The Manila Times
Cullinan Therapeutics' CLN-049 Receives FDA Fast Track Designation for Treatment of Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
FDA grants fast track designation to Cullinan’s AML therapy - Investing.com
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells 4,000 Shares of Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 7.6%Should You Sell? - MarketBeat
Cullinan Oncology stock price target raised to $36 at Jones Trading - Investing.com Nigeria
Why Cullinan Therapeutics (CGEM) Is Up 38.1% After FDA Filing for EGFR-mutant Lung Cancer Drug - Sahm
Buy Rating for Cullinan Therapeutics Driven by Promising AML Treatment Developments and Strong Market Potential - TipRanks
Foresite Capital Management VI LLC Lowers Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer (PR Newswire) - Aktiellt
Cullinan Therapeutics (NASDAQ:CGEM) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Investors Purchase High Volume of Call Options on Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
Is Cullinan Therapeutics Inc (CGEM) positioned for future growth? - Setenews
Cullinan Oncology stock price target raised to $38 at BTIG on promising AML data - Investing.com Canada
Taiho, Cullinan file rolling NDA on phase I/II zipalertinib data - BioWorld MedTech
BTIG Maintains Cullinan Therapeutics (CGEM) Buy Recommendation - Nasdaq
Cullinan Therapeutics (CGEM) Receives PT Upgrade from BTIG Analy - GuruFocus
Cullinan Therapeutics price target raised to $38 from $32 at BTIG - TipRanks
Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Cullinan Management Ends Development of CLN-617 - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $26.00 - Defense World
Cullinan Therapeutics Inc Azioni (CGEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):